A 43-year-old woman with a two-year history of Parkinson's disease who struggled with accepting her diagnosis, anxious rumination, and pessimism received four sessions of high-dose psychedelic-assisted psychotherapy (psilocybin) within one year. The treatment was well tolerated and significantly improved her pessimistic outlook, reduced anxious worries about future disability, and enhanced general well-being. Psychometric scores for depression, anxiety, and optimism improved, though apathy did not change. Motor symptoms remained stable. The patient's greater acceptance of Parkinson's disease allowed her to accept adjustments to her medication. The authors suggest psychedelic-assisted psychotherapy could be a safe, useful option for Parkinson's patients with dispositional pessimism and difficulty accepting their disease, but note that controlled trials are needed to confirm these results.
Psychedelics like psilocybin and LSD, acting through 5-HT2A receptors, rapidly and lastingly improve depression and anxiety by modulating neuroplasticity and brain connectivity. They may also help with addictions, post-traumatic stress, and obsessive-compulsive disorder. This article explores their potential in Parkinson's disease, both for treating depression, anxiety, and impulse control disorders and for neuroprotection. Psychedelics stimulate synaptogenesis, increase brain-derived neurotrophic factor, and have anti-inflammatory effects. However, clinical trials are needed to confirm safety and efficacy in Parkinson's disease.